axie bet88 sign up

axie bet88 sign up NEW DELHI (AP) — Prime Minister Narendra Modi’s Hindu nationalist party headed for a victory Saturday in state elections in politically significant Maharashtra while the opposition won mineral-rich Jharkhand state. Polling in the two states are seen as a test of Modi's popularity after his party returned to power in June national elections but was forced to form a coalition government with help from regional partners. India’s Election Commission said Modi’s Bharatiya Janata Party and its allies have already won 183 of 288 seats and were leading in another 48 seats in Maharashtra, India’s wealthiest state and home to the country's financial and entertainment capital, Mumbai. The opposition Congress party and its allies have won 50 of 81 seats and were leading in another four seats in eastern Jharkhand state, according to the commission. It said vote counting was nearing completion and final results were expected later on Saturday. Modi's BJP and a Hindu nationalist ally currently rule Maharashtra, where Hindus constitute nearly 80% and Muslims 11.5% of its 126 million people. An opposition alliance, including the Congress party, is in power in eastern Jharkhand state. The BJP has used slogans such as, “If you divide, then you will die,” and “If we are united, then we are safe,” to attract majority Hindu votes. The opposition accused it of trying to polarize voters along Hindu-Muslim religious lines. Meanwhile, Priyanka Gandhi from Congress party, the 52-year-old scion of the Nehru-Gandhi political dynasty, is set to make her debut in Parliament after winning the race against a Communist Party candidate by a huge margin of over 400,000 votes in the Wayanad seat in southern Kerala state. She contested a special election after her brother Rahul, who was elected in two constituencies in June, had to vacate one. Her mother Sonia Gandhi is already in Parliament. The BJP had hoped to attract women with a plan that provides 1,500 rupees ($18) a month to over 20 million women in the 21-65 age group whose annual family income is less than 250,000 rupees ($3,010). The Congress party promised women double that amount and free transportation in government buses. The opposition also hoped to capitalize on the simmering disaffection with high youth unemployment, inflation and low crop prices during the BJP’s rule. In September, Congress was able to secure votes in India’s insurgency-wracked Jammu and Kashmir after a 10-year gap. But Modi’s BJP regained momentum in October and won the Haryana state election even though pollsters had predicted an easy victory for Congress.

History Suggests This Defense Stock Will Outperform the Defense MarketThe end of the year is the perfect time to reflect on your portfolio. But sometimes, that can lead to anxiety if there is a rift between where your portfolio is and where you want it to be. Instead of trying to trade your way out of discomfort, a better approach is to engage in exercises that can help set the stage for compounding your wealth over time. Here are investment portfolio actions worth taking before the end of the year. Conduct a portfolio review Investing in the art of putting capital to work in quality companies, identifying risks that can derail an investment thesis, and sticking with winning companies over time -- these are all part of a portfolio review. Having an investment thesis for each asset you own is paramount. Some can be short, whereas others can be long. But it's essential to know what a company does, what it is trying to do, and why you believe it is worth putting your hard-earned money into. You can also make investment theses for companies you don't own but are high on your watchlist so that you can have the conviction to buy them when it makes sense for you to do so. As an example, here's the essence of my investment thesis on Microsoft ( MSFT 0.21% ) : Microsoft is an industry-leading company with exposure to several end markets. It has evolved from mediocre sales growth and weak margins to a high-margin cash cow -- largely thanks to the build-out of Microsoft Cloud and product upgrades of existing software. Microsoft is monetizing artificial intelligence (AI) throughout its product suite, from Microsoft 365 to GitHub, Azure, and more. The company is well diversified across hardware and software. It owns LinkedIn and has a powerful place in gaming with Xbox and Activision Blizzard. Microsoft generates plenty of excess earnings to pay a growing dividend and repurchase more than enough stock to offset stock-based compensation, which grows earnings per share by decreasing the outstanding share count and making Microsoft a better value. Because Microsoft has more cash, cash equivalents, and marketable securities than debt on its balance sheet, it is well positioned to endure an industrywide downturn and even take market share or make timely acquisitions. Microsoft's 36.1 price-to-earnings (P/E) ratio is above its historical levels, putting pressure on the company to deliver outsized growth or risk facing a sell-off. But long term, Microsoft has plenty of levers to pull for growing earnings, making it worth holding even if the stock price goes down in the near term. Aligning allocation with risk tolerance Another mistake investors can make is losing sight of their portfolio allocation. Technically, a portfolio's allocation changes anytime the market is open with movements in stock prices. But the bigger picture is to identify when there is a substantial change in your portfolio. For example, let's say you invested 10% of a $10,000 portfolio in Nvidia and 10% into Meta Platforms a year ago. Nvidia is up 218.9% during that period, while Meta is up 91.8%. Let's assume the other 80% of the portfolio performed in lockstep with the S&P 500 and is up 33.2% during that period.Here's a look at how that hypothetical portfolio would change in just one year. Holding Starting Value Percentage of Portfolio Gain New Value New Percentage of Portfolio Nvidia $1,000 10% 218.9% $3,189 20.2% Meta Platforms $1,000 10% 91.8% $1,918 12.2% S&P 500 $8,000 80% 33.2% $10,656 67.6% Nvidia now makes up around 20% of the portfolio instead of 10%. And even though the Meta investment nearly doubled, its percentage of the portfolio actually didn't change that much because it was offset by outsized gains from Nvidia and good gains from the S&P 500. If you look at how your allocation has evolved and are ok with it, then you may not need to do anything. But you could also find you are way more allocated toward a certain company, theme, or sector than you thought. The knee-jerk reaction may be to sell out of those winners and rebalance into other names. But that strategy can result in regret if you sell a stock just because it went up. It's better to have a clear reason for selling a stock. The best approach for addressing an uncomfortable allocation is to put new capital to work into other high-conviction areas. For example, if someone felt their portfolio is too concentrated in megacap, tech-focused growth companies, they could consider investing in safe dividend stocks , growth companies from other sectors , or a diversified exchange-traded fund (ETF) like the Vanguard Mega Cap Value ETF . Suppose you are in the capital-preservation phase of your financial journey and no longer regularly putting new capital to work in the market. In that case, you may need to take the necessary actions to balance risk and potential reward by investing in companies that are valued based on what they are doing today rather than their potential growth. The next lesson applies to investors in the capital-accumulation phase, so if you're in the preservation stage, feel free to skip it. Set savings and investment goals for 2025 It is just as important to set clear savings goals for 2025 as it is to update your watchlist of stocks you want to buy. Simple math shows us that it is far better to be a great saver and a mediocre investor than a bad saver and an exceptional investor. As an example, let's say two people start with $20,000 and have a 10-year time horizon. Person A earns an average annual return of 10% a year and additionally saves $5,000 per year that goes into the same investment portfolio. At the end of the 10-year period, they end up with a tidy sum of $131,561.97. Person B achieves 20% average annual returns but doesn't contribute any savings. Despite returns that rival Warren Buffett's average from 1965 to 2023, they would end up with $123,834.73 after the 10-year period for the same $20,000 originally invested. It's still highly impressive, but if they would have also saved $5,000 per year, they would end up with over $253,000 at the end of the 10-year period. Position yourself to endure the unexpected Instead of getting caught up in speculating what the stock market will do in 2025, it is a far better use of time and energy to review what you can control: your investments and savings habits. Having a firm grip on these factors makes it far easier to filter out the noise and focus on achieving your financial goals. This can be especially helpful when the market is going down and volatility is high.

Google's Willow Chip: Future of Quantum Technology and ApplicationsAvior Wealth Management LLC grew its position in shares of Intra-Cellular Therapies, Inc. ( NASDAQ:ITCI – Free Report ) by 3.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,473 shares of the biopharmaceutical company’s stock after purchasing an additional 131 shares during the period. Avior Wealth Management LLC’s holdings in Intra-Cellular Therapies were worth $327,000 at the end of the most recent quarter. Other hedge funds and other institutional investors have also modified their holdings of the company. Summit Securities Group LLC purchased a new stake in Intra-Cellular Therapies in the 2nd quarter worth approximately $56,000. Capital Performance Advisors LLP acquired a new position in Intra-Cellular Therapies in the third quarter valued at $74,000. CWM LLC boosted its stake in Intra-Cellular Therapies by 83.9% in the 2nd quarter. CWM LLC now owns 1,372 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 626 shares during the last quarter. Covestor Ltd raised its stake in Intra-Cellular Therapies by 40.4% during the third quarter. Covestor Ltd now owns 1,811 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 521 shares during the period. Finally, Assetmark Inc. boosted its holdings in shares of Intra-Cellular Therapies by 9.1% in the 3rd quarter. Assetmark Inc. now owns 2,477 shares of the biopharmaceutical company’s stock valued at $181,000 after purchasing an additional 207 shares during the last quarter. 92.33% of the stock is currently owned by hedge funds and other institutional investors. Insider Transactions at Intra-Cellular Therapies In other news, CEO Sharon Mates sold 34,396 shares of Intra-Cellular Therapies stock in a transaction on Friday, August 30th. The stock was sold at an average price of $72.84, for a total transaction of $2,505,404.64. Following the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at approximately $77,962,764.36. This trade represents a 3.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link . Also, President Michael Halstead sold 22,869 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total transaction of $2,038,085.28. The disclosure for this sale can be found here . Over the last three months, insiders sold 97,778 shares of company stock worth $7,524,436. Company insiders own 2.60% of the company’s stock. Analyst Upgrades and Downgrades Read Our Latest Report on ITCI Intra-Cellular Therapies Trading Up 0.3 % Shares of Intra-Cellular Therapies stock opened at $85.69 on Friday. The stock has a market capitalization of $9.08 billion, a price-to-earnings ratio of -98.49 and a beta of 0.97. Intra-Cellular Therapies, Inc. has a twelve month low of $58.14 and a twelve month high of $93.45. The business’s 50 day simple moving average is $79.05 and its 200-day simple moving average is $74.66. Intra-Cellular Therapies ( NASDAQ:ITCI – Get Free Report ) last issued its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company had revenue of $175.40 million during the quarter, compared to analyst estimates of $172.30 million. During the same period in the prior year, the business earned ($0.25) earnings per share. Intra-Cellular Therapies’s quarterly revenue was up 39.0% on a year-over-year basis. Sell-side analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year. Intra-Cellular Therapies Company Profile ( Free Report ) Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. See Also Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies, Inc. ( NASDAQ:ITCI – Free Report ). Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter .

A look at how some of Trump's picks to lead health agencies could help carry out Kennedy's overhaul